Based on company statement 2017 is $44K per surgery. Their biggest struggle is ramping up the insurance companies. Success will show incrementally. The proof will be in the back half of 2017. That is why the relatively low price target. Also they are still working on expanding use of Epicel. Monetization can be a bitch, but they have a good plan and if they can keep ATM to a minimum it will speed up whole hearted confidence from the market.
News 
Market Data 
Discover 
